These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20870708)

  • 1. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
    Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
    Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
    Widhalm G; Wolfsberger S; Preusser M; Woehrer A; Kotter MR; Czech T; Marosi C; Knosp E
    Cancer; 2009 Mar; 115(5):1070-80. PubMed ID: 19156926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
    McCormack AI; Wass JA; Grossman AB
    Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pituitary neoplasms with temozolomide: a review.
    Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
    Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
    Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
    Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of temozolomide in the treatment of aggressive pituitary tumors.
    Liu JK; Patel J; Eloy JA
    J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
    Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
    Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide in aggressive pituitary adenomas and carcinomas.
    Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
    J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
    Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
    Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
    McCormack AI; McDonald KL; Gill AJ; Clark SJ; Burt MG; Campbell KA; Braund WJ; Little NS; Cook RJ; Grossman AB; Robinson BG; Clifton-Bligh RJ
    Clin Endocrinol (Oxf); 2009 Aug; 71(2):226-33. PubMed ID: 19067722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How effective is temozolomide for treating pituitary tumours and when should it be used?
    Halevy C; Whitelaw BC
    Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of temozolomide in aggressive pituitary tumors: case report.
    Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
    Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
    Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
    Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.
    Takeshita A; Inoshita N; Taguchi M; Okuda C; Fukuhara N; Oyama K; Ohashi K; Sano T; Takeuchi Y; Yamada S
    Eur J Endocrinol; 2009 Oct; 161(4):553-9. PubMed ID: 19589911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
    Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
    Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
    Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
    J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.